Crescent Innovations, Inc. has developed a regenerative technology for joints (U.S. Patent 7,501,396). This platform technology promises to be the first new material used in viscosupplementation in almost 20 years and would be a breakthrough technology for treating Osteoarthritis (OA) of the knee and other joints.
Estimates are that as many as 27 million Americans seek treatment for chronic pain associated with OA every year.
Early stages of OA, which first present themselves as early as 35 years, are treated with oral anti-inflammatory drugs. At the end stage of the disease, the joint may be replaced, but the average age of joint replacement is 60 to 65 years.
Viscosupplementation was developed in the 1990’s and was supposed to be a long term viable intermediary treatment. This has not turned out to be the case. Currently all viscosupplementation products approved throughout the world use a single ingredient. They typically perform only marginally better than placebo, and sometimes not even that well.
Crescent Innovations, Inc. has data suggesting that our new technology (PGA-OA) reduces inflammation and pain better than current technology. PGA-OA has passed all pre-clinical safety tests and is ready for clinical study.